Answers are grounded in this paper and cite their sources.
Meta-analysis reveals doxorubicin-loaded graphene therapy significantly reduces tumor volume in xenograft models, suggesting promise for clinical applications.
OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in breast cancer xenograft tumors. Hedges' g was used as the effect size measure, and standardized mean differences (SMDs) were pooled using a random-effects model. Heterogeneity, publication bias, subgroup analyses, sensitivity analyses, and qualitatively reported secondary endpoints were assessed. Leave-one-out sensitivity analyses yielded pooled SMDs from -2.09 to -2.37. Funnel plot inspection and Egger's test suggested mild small-study asymmetry, but Trim-and-Fill correction did not change the direction or significance of the result. Secondary endpoint extraction showed limited survival, toxicity, biodistribution, and clearance reporting, supporting short-term tolerability but not definitive clinical translation. CONCLUSION: DOX-loaded graphene nanoplatform CPT was associated with significantly greater suppression of RTV than PTT alone in breast cancer xenograft models. The evidence supports a robust preclinical antitumor association while highlighting the need for standardized survival, long-term toxicity, biodistribution, and elimination studies before clinical application.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: